Valuation Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
NYSE
06:00:02 16/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 85.74 USD | +0.26% |
|
-1.13% | +0.57% |
| 11/09 | Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision | MT |
| 27/08 | Edwards Lifesciences Insider Sold Shares Worth $2,894,440, According to a Recent SEC Filing | MT |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,883 | 46,128 | 46,246 | 43,663 | 49,471 | 49,421 | - | - |
| Change | - | -42.97% | 0.25% | -5.58% | 13.3% | -0.1% | - | - |
| Enterprise Value (EV) 1 | 80,616 | 45,956 | 45,198 | 40,285 | 45,843 | 45,790 | 44,226 | 42,410 |
| Change | - | -42.99% | -1.65% | -10.87% | 13.8% | -0.12% | -3.42% | -4.11% |
| P/E | 54.4x | 30.6x | 33.2x | 10.6x | 46.6x | 33.9x | 26x | 23.1x |
| PBR | 13.9x | 7.82x | 6.99x | 4.36x | 4.79x | 4.66x | 4.05x | 3.76x |
| PEG | - | 12.14x | -5.79x | 0x | -0.6x | 0.9x | 0.9x | 1.8x |
| Capitalization / Revenue | 15.5x | 8.57x | 7.7x | 8.03x | 8.15x | 7.31x | 6.65x | 6.04x |
| EV / Revenue | 15.4x | 8.54x | 7.53x | 7.41x | 7.56x | 6.77x | 5.95x | 5.19x |
| EV / EBITDA | 46.6x | 23.7x | 24.1x | 24.1x | 25.5x | 21.4x | 18.6x | 15.8x |
| EV / EBIT | 50.6x | 25.6x | 26.1x | 26.6x | 27.9x | 23.2x | 20x | 17.1x |
| EV / FCF | 57.3x | 47.2x | 47.9x | 139x | 34.3x | 53.9x | 27.5x | 23.3x |
| FCF Yield | 1.74% | 2.12% | 2.09% | 0.72% | 2.91% | 1.85% | 3.64% | 4.29% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.38 | 2.44 | 2.3 | 6.97 | 1.83 | 2.531 | 3.304 | 3.718 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5,232 | 5,382 | 6,005 | 5,440 | 6,068 | 6,760 | 7,429 | 8,177 |
| EBITDA 1 | 1,729 | 1,936 | 1,879 | 1,670 | 1,800 | 2,137 | 2,384 | 2,687 |
| EBIT 1 | 1,594 | 1,796 | 1,734 | 1,514 | 1,644 | 1,971 | 2,212 | 2,484 |
| Net income 1 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,435 | 1,897 | 2,054 |
| Net Debt 1 | -267 | -172.7 | -1,048 | -3,378 | -3,628 | -3,631 | -5,195 | -7,011 |
| Reference price 2 | 129.55 | 74.61 | 76.25 | 74.03 | 85.25 | 85.74 | 85.74 | 85.74 |
| Nbr of stocks (in thousands) | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 576,400 | - | - |
| Announcement Date | 26/1/22 | 31/1/23 | 6/2/24 | 11/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.79x | 6.76x | 21.37x | -.--% | 49.29B | |
| 30.49x | 5.39x | 20.64x | 0.3% | 227B | |
| 34.28x | 6.21x | 19.68x | 0.69% | 143B | |
| 40.96x | 10.8x | 23.84x | -.--% | 134B | |
| 17x | 3.47x | 11.31x | -.--% | 65.29B | |
| 19.37x | 2.33x | 11.69x | 2.63% | 50.09B | |
| 28.59x | 5.68x | 19.28x | 0.7% | 41.39B | |
| 71.78x | 6.85x | 20.89x | -.--% | 40.28B | |
| 19.1x | 5.33x | 13.75x | 1.19% | 31.9B | |
| 42.1x | 6.77x | 23.94x | -.--% | 31.44B | |
| Average | 33.75x | 5.96x | 18.64x | 0.55% | 81.3B | |
| Weighted average by Cap. | 33.26x | 6.30x | 19.54x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EW Stock
- Valuation Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
